AI-28 RECURRENT GLIOBLASTOMAS AFTER TREATMENT WITH BEVACIZUMAB

Bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, has been evaluated in the treatment of patients with primary or recurrent glioblastoma. We aimed to characterize neuropathological and molecular features in recurrent malignant gliomas after failure of Bevacizumab tr...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Tabatabai, Ghazaleh, Felsberg, Jörg, Sabel, Michael, Kaulich, Kerstin, Hofer, Silvia, Westphal, Manfred, Weller, Michael, Reifenberger, Guido
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2014
Aiheet:
Abstracts
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217867/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou238.28
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia